Qitan Technology

Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenient instrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics.

Qitan Technology headquartered in Asia, operates in the Biotechnology, Health Care sector. The company focuses on Biotechnology and has secured $11.0B in funding across 56 round(s). With a team of 51-100 employees, Qitan Technology is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Qitan Technology, raised $14.1M. Discover more about their projects, partnerships, and impact on our platform.